Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Shionogi & Co., Ltd.
  6. News
  7. Summary
    4507   JP3347200002

SHIONOGI & CO., LTD.

(4507)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about SHIONOGI & CO., LTD.
01/18Shionogi & Co-Notice Regarding the Initiation of an Active Control Neutralizing Antibod..
AQ
01/18Shionogi Begins Comparative Phase III Trial of COVID-19 Drug
MT
01/17SHIONOGI : Notice Regarding the Initiation of an Active Control Neutralizing Antibody Comp..
PU
01/17Shionogi & Co., Ltd. Announces Notice Regarding the Initiation of Active Control Neutra..
CI
01/13Pfizer says it applied for Japan gov't approval for oral COVID-19 drug
RE
01/06Shionogi Announces Commitment to Fight COVID-19
AQ
2021Shionogi Signs up to $41 Million Commercialization Contract for Insomnia App
MT
2021Shionogi Starts COVID-19 Vaccine Trial in Vietnam
MT
2021SHIONOGI : Announces a Commercialization Agreement with SUSMED for a Digital Therapeutic A..
PU
2021Shionogi & Co., Ltd. Announces Commercialization Agreement with SUSMED Co., Ltd. for Di..
CI
2021SHIONOGI : Notice Regarding the Initiation of a Global Phase 3 Clinical Trial for COVID-19..
PU
2021Shionogi & Co., Ltd. Announces Initiation of a Global Phase 3 Clinical Trial for COVID-..
CI
2021Shionogi Has Been Recognized for Leadership in Corporate Sustainability by CDP Rated as..
AQ
2021Shionogi Updates on Initiatives Against Omicron Variant
MT
2021Shionogi's COVID pill under development effective against Omicron
AQ
More most relevant news
All news about SHIONOGI & CO., LTD.
01/18Shionogi & Co-Notice Regarding the Initiation of an Active Control Neutralizing Antibod..
AQ
01/18Shionogi Begins Comparative Phase III Trial of COVID-19 Drug
MT
01/17SHIONOGI : Notice Regarding the Initiation of an Active Control Neutralizing Antibody Comp..
PU
01/17Shionogi & Co., Ltd. Announces Notice Regarding the Initiation of Active Control Neutra..
CI
01/13Pfizer says it applied for Japan gov't approval for oral COVID-19 drug
RE
01/06Shionogi Announces Commitment to Fight COVID-19
AQ
01/05Nikkei 226 Edges Up 0.1% on Softer Yen Outlook
MT
2021Shionogi Signs up to $41 Million Commercialization Contract for Insomnia App
MT
2021Shionogi Starts COVID-19 Vaccine Trial in Vietnam
MT
2021SHIONOGI : Announces a Commercialization Agreement with SUSMED for a Digital Therapeutic A..
PU
More news
News in other languages on SHIONOGI & CO., LTD.
01/17Shionogi & Co., Ltd. annonce un avis concernant le lancement d'un essai clinique compar..
01/05Le Nikkei 226 progresse de 0,1 % en raison de perspectives plus favorables pour le yen
01/05MÄRKTE ASIEN/Gewinnmitnahmen - Yen-Schwäche stützt Tokio
2021Shionogi & Co., Ltd. annonce la signature d'un accord de commercialisation avec SUSMED ..
2021Shionogi & Co., Ltd. annonce le lancement d'un essai clinique mondial de phase 3 pour l..
2021JAPON : Un comité de santé approuve le traitement oral contre le COVID-19 de Merck
2021Panel de salud de Japón aprueba el tratamiento oral contra el COVID-19 de Merck
2021Japon-Un comité de santé approuve le traitement oral contre le COVID-19 de Merck
2021SHIONOGI : son médicament Covid atténue les symptômes de l'omicron
2021GLAXOSMITHKLINE : le premier traitement injectable de prévention du VIH produit par ViiV H..
More news
Analyst Recommendations on SHIONOGI & CO., LTD.
2020GSK's long-acting injection beats Truvada in HIV prevention trial
RE
2017Gilead challenges GSK with strong HIV drug data
RE
2013Analysts see possible windfall from GSK spin-offs
RE
More recommendations
Press releases
01/18Shionogi & Co-Notice Regarding the Initiation of an Active Control Neutralizing Antibod..
AQ
01/17SHIONOGI : Notice Regarding the Initiation of an Active Control Neutralizing Antibody Comp..
PU
01/06Shionogi Announces Commitment to Fight COVID-19
AQ
2021SHIONOGI : Announces a Commercialization Agreement with SUSMED for a Digital Therapeutic A..
PU
2021SHIONOGI : Notice Regarding the Initiation of a Global Phase 3 Clinical Trial for COVID-19..
PU
More press releases
Upcoming event on SHIONOGI & CO., LTD.
01/31/22